{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:06Z","timestamp":1790166186317,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Specific imatinib-resistant BCR-ABL1 mutations (Y253H, E255K\/V, T315I, F317L, and F359V\/C) predict failure of second-line nilotinib or dasatinib therapy in patients with chronic myeloid leukemia; however, such therapy also fails in approximately 40% of patients in the chronic phase of this disease who do not have these resistant mutations. We investigated whether sensitive mutation analysis could identify other poor-risk subgroups. Analysis was performed by direct sequencing and sensitive mass spectrometry on 220 imatinib-resistant patients before they began nilotinib or dasatinib therapy. Patients with resistant mutations by either method (n = 45) were excluded because inferior response was known. Of the remaining 175 patients, 19% had multiple mutations by mass spectrometry versus 9% by sequencing. Compared with 0 or 1 mutation, the presence of multiple mutations was associated with lower rates of complete cytogenetic response (50% vs 21%, P = .003) and major molecular response (31% vs 6%, P = .005) and a higher rate of new resistant mutations (25% vs 56%, P = .0009). Sensitive mutation analysis identified a poor-risk subgroup (15.5% of all patients) with multiple mutations not identified by standard screening.<\/jats:p>","DOI":"10.1182\/blood-2011-08-375535","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T01:32:53Z","timestamp":1325295173000},"page":"2234-2238","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile"],"prefix":"10.1182","volume":"119","author":[{"given":"Wendy T.","family":"Parker","sequence":"first","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musei","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish S.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"School of Molecular and Biomedical Science and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Adelaide, Adelaide, Australia; and"},{"name":"Department of Hematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"35","key":"2019111807231907100_B1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807231907100_B2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111807231907100_B3","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807231907100_B4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"2019111807231907100_B5","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111807231907100_B6","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111807231907100_B7","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"issue":"32","key":"2019111807231907100_B8","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.","volume":"29","author":"Parker","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807231907100_B9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111807231907100_B10","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2019111807231907100_B11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial.","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807231907100_B12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111807231907100_B13","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"2019111807231907100_B14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807231907100_B15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/ng1768","article-title":"Genetic clonal diversity predicts progression to esophageal adenocarcinoma.","volume":"38","author":"Maley","year":"2006","journal-title":"Nat Genet"},{"issue":"7","key":"2019111807231907100_B16","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood-2002-10-3207","article-title":"p210 BCR\/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation.","volume":"102","author":"Canitrot","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2019111807231907100_B17","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111807231907100_B18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/leu.2008.78","article-title":"BCR\/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.","volume":"22","author":"Koptyra","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111807231907100_B19","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"2019111807231907100_B20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10585-007-9134-2","article-title":"Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions.","volume":"25","author":"Lyons","year":"2008","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"2019111807231907100_B21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/leu.2008.3","article-title":"BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.","volume":"22","author":"Liu","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111807231907100_B22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3324\/haematol.2010.034173","article-title":"Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.","volume":"96","author":"Soverini","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2019111807231907100_B23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2010.039321","article-title":"Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.","volume":"96","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"2019111807231907100_B24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"issue":"27","key":"2019111807231907100_B25","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111807231907100_B26","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/10\/2234\/1348470\/zh801012002234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/10\/2234\/1348470\/zh801012002234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:31:07Z","timestamp":1574080267000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/10\/2234\/29521\/Poor-response-to-secondline-kinase-inhibitors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,8]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-375535","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,8]]}}}